FONT-SIZE Plus   Neg

Silence Therapeutics Promotes Tony Sedgwick To CEO - Quick Facts

Silence Therapeutics plc (SLN.L) announced the promotion of Tony Sedgwick to the role of chief executive from chief business officer, effective immediately, and the departure of Thomas Christély who has resigned as a director of the company for personal reasons but would ensure a smooth transition.

Anthony David Sedgwick, with an extensive experience from European life science companies including over 15 years at Roche, joined Silence in September 2011 to lead a new business development team. Prior to joining
Silence, Tony was CEO of Novacta and Chairman of the Norwegian biotech company Plastid AS. Earlier, Tony was also CEO of two acquired companies namely Daniolabs Ltd. and Cambridge Biotechnology Ltd.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Ford Motor Company on Thursday reported a 56 percent fall in profit for the third quarter from last year, reflecting safety-recall expenses, product launch costs and lower profit in North America. However, adjusted earnings per share beat analysts' estimates. Social media site Twitter Inc. (TWTR) reported a narrower loss for the third-quarter quarter, while quarterly revenue increased 8% from the prior year. Adjusted earnings per share topped analysts' expectations. It will reduce about 9% of its global workforce. It updated its outlook for the full year 2016 and provided guidance for the fourth quarter of 2016. Dow Chemical Co. (DOW) reported a profit for the third-quarter declined about 44 percent from the prior year, reflecting a $0.13 per share charge related to the Dow Corning ownership restructure and a $0.11 per share charge for transactions and productivity actions. Results in the year-ago period reflect a $0.32 per share gain from the Agrofresh divestiture.
comments powered by Disqus
Follow RTT